Capricor Therapeutics

Capricor Therapeutics, Inc., based in Beverly Hills, focuses on developing and commercializing biological therapies for rare disorders, with a primary emphasis on Duchenne muscular dystrophy (DMD). The company aims to address significant unmet medical needs in the healthcare sector across the United States and Canada. Capricor's flagship product, Deramiocel (CAP-1002), is designed to improve skeletal muscle and cardiac function in DMD patients.

Capricor has achieved notable milestones, including positive Type-B and pre-BLA meetings with the FDA for its CAP-1002 program, which aims to expedite the Biologics License Application pathway. The company has also reported long-term benefits of Deramiocel in clinical studies and has been included in the Russell 3000® and Russell Microcap® Indexes. These accomplishments underscore Capricor's impact on advancing treatments for rare diseases.